All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NOUS-PEV
Therapeutic Area: Oncology Product Name: NOUS-PEV
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Details:
NOUS-PEV will be investigated in the study as a potential treatment for patients with either locally advanced 1L melanoma or 1L non-small cell lung cancer (NSCLC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ixovex-1
Therapeutic Area: Oncology Product Name: Ixovex-1
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: PsiVac
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 08, 2021
Details:
Under the terms of the parties’ strategic agreement, PsiVac will grant Lonza the exclusive right to cGMP manufacture the Ixovex-1 product.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NILK-2301
Therapeutic Area: Oncology Product Name: NILK-2301
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: LamKap Bio Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 18, 2020
Details:
Lonza will provide cell line and process development, drug substance manufacturing and drug product services of LamKap's two fully human bispecific antibody products, NILK-2301 and NILK-2401.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Derazantinib,Erdafitinib
Therapeutic Area: Oncology Product Name: ARQ 087
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
The preclinical derazantinib data may provide an explanation for differences in reported adverse event profiles between various FGFR kinase inhibitors. Furthermore, derazantinib shows promising efficacy in patient-derived tumor models with gene aberrations in FGFR1-3.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T3P-Y058-739
Therapeutic Area: Oncology Product Name: T3P-Y058-739
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $27.4 million Upfront Cash: Undisclosed
Deal Type: Financing July 22, 2020
Details:
T3 Pharma will use the funds primarily to progress its lead candidate, T3P-Y058-739, through clinical studies. The Phase 1/2 clinical study in solid tumors is planned to start in early 2021.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
